(2005) 288:R1695706

Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic injection 0.5 mg + basal insulin MET 10.7% with Ozempic injection 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified

Engage in Regular Physical Activity Incorporating regular exercise into your routine not only aids in weight loss but also enhances overall health and well-being
How long does semaglutide take to work for weight loss
Before starting GLP-1 treatment , inform your GP about: Current or previous anxiety disorders , including generalised anxiety disorder, panic disorder, social anxiety, or health anxiety Other mental health conditions such as depression, eating disorders, or obsessive-compulsive disorder Current psychiatric medications , as weight loss may affect medication requirements though GLP-1 medications themselves have few direct drug interactions Previous experiences with weight loss or diabetes medications and any associated mood changes Your support network and coping strategies for managing stress and anxiety Your GP can help establish baseline mental health status and develop a monitoring plan